Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis

Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therap...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychopharmacology (Oxford) 2021-03, Vol.35 (3), p.273-278
Main Authors: Kuzin, Maxim, Haen, Ekkehard, Hiemke, Christoph, Bochon, Benjamin, Bochon, Karolina, Gründer, Gerhard, Paulzen, Michael, Schoretsanitis, Georgios
Format: Article
Language:English
Subjects:
Antipsychotics
Bioavailability
Body composition
Body mass index
Body weight
Chi-square test
Clozapine
Drug dosages
Enzymatic activity
Pharmacokinetics
Plasma
Sex differences
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Knowledge regarding the impact of body composition measures on pharmacokinetics of antipsychotics is limited. Aims: Our aim was to investigate the impact of body weight and body mass index on clozapine pharmacokinetics using a therapeutic drug monitoring database. Methods: A large therapeutic drug monitoring dataset of clozapine plasma concentrations considering three patient subgroups was analysed: a control group (CLZ0, 20–30 kg/m2, n=266), a group with high body mass index (CLZhigh, body mass index ⩾30 kg/m2, n=162) and with low body mass index values (CLZlow, body mass index
ISSN:0269-8811
1461-7285
DOI:10.1177/0269881120985166